Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of intra-articular LRX712 in knee osteoarthritis
NL-OMON46705Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing LRX712 ascending dose with Placebo (2 arms). Primary endpoints: Adverse events, 24-hour Holter monitoring and 3 more. Started Dec 2017; status: active, not recruiting.
02
Drugs
LRX712
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON46705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46705.